Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Alembic Limited is a veteran manufacturer of bulk drugs and pharmaceuticals for human and animal healthcare in India. Founded in 1907, it has developed strong expertise in APIs and formulations, with significant production facilities in Vadodara and Solan.
Alembic's history of pharmaceutical innovation includes significant developments such as the launch of Erythromycin under Althrocin in 1972, which became a bestseller in India by 1997.
The company has diversified its business to include real estate and power generation sectors, leveraging its captive power plant operations and launching notable real estate projects like Samsara and VEDA.
Alembic's strategic ventures include the expansion of its API capacities and acquiring significant pharmaceutical and API facilities, boosting its operational capabilities over the years.
Realty
Residential, Commercial Projects
2,311 Cr
High Risk
7.3
33.4
0.1
0.9
122.40
70.64
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Alembic Ltd (ALEMBICLTD) is currently trading at 90.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Alembic Limited is a veteran manufacturer of bulk drugs and pharmaceuticals for human and animal healthcare in India. Founded in 1907, it has developed strong expertise in APIs and formulations, with significant production facilities in Vadodara and Solan. Alembic's history of pharmaceutical innovation includes significant developments such as the launch of Erythromycin under Althrocin in 1972, which became a bestseller in India by 1997. The company has diversified its business to include real estate and power generation sectors, leveraging its captive power plant operations and launching notable real estate projects like Samsara and VEDA. Alembic's strategic ventures include the expansion of its API capacities and acquiring significant pharmaceutical and API facilities, boosting its operational capabilities over the years.
Over the past 52 weeks, Alembic Ltd has traded between a low of ₹70.64 and a high of ₹122.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Alembic Ltd has a market capitalization of approximately 2,277.14. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Alembic Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 7.17 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,277.14 Cr, Alembic Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Alembic Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Alembic Ltd is 7.17. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue from operations rose 17% YoY to ₹1,770 crore, while net profit was reported at ₹157 crore, down about 12% YoY.
Revenue from operations rose 17% YoY to ₹1,770 crore, while net profit for the quarter was reported at ₹157 crore (also cited around ₹156 crore in one disclosure).
Alembic said it received USFDA approval for its generic Lamotrigine tablets used to treat seizures, with an ANDA therapeutically equivalent to GlaxoSmithKline’s Lamictal.
Dapagliflozin is a medication used to treat type 2 diabetes and reduce the risk of heart failure. The final USFDA approval is significant for Alembic as it allows the company to launch a generic version in the U.S. market, which is estimated to be worth over $10 billion, and includes a 180-day shared exclusivity period.
Bearish
3
Neutral
8
Bullish
3
Bearish
16
Neutral
8
Bullish
22
Bearish
13
Neutral
0
Bullish
19
AGM/EGM Notice
Alembic Ltd sent a specimen letter to shareholders without registered emails giving web-link to access the Annual Report FY2025-26. AGM scheduled for 2026-08-11 at 17:00 IST via VC; e-voting, record and dividend dates provided.
AGM/EGM Notice
Alembic Ltd sent a specimen letter to shareholders without registered email providing web-link to the Annual Report FY 2025-26. 119th AGM on 2026-08-11 at 17:00 IST via VC; e-voting 2026-08-08 09:00 to 2026-08-10 17:00; record date for dividend 2026-08-04.
AGM/EGM Notice
Alembic Ltd published a newspaper notice (Indian Express & Financial Express) on 11-Jul-2026 informing members of the schedule of the 119th AGM, dispatch of the Annual Report for FY2025-26 and e‑voting procedure.
Dividend
Alembic Ltd has fixed 4 August 2026 as the Record Date to determine members eligible for dividend for FY ended 31 Mar 2026; payment subject to approval at the AGM on 11 August 2026.
Dividend
Alembic Ltd has fixed 2026-08-04 as the record date to determine shareholders eligible for dividend for FY ended 2026-03-31; dividend payment subject to approval at the AGM on 2026-08-11.
AGM/EGM Notice
Alembic Ltd: Notice of 119th AGM on 2026-08-11 at 17:00 IST via VC/OAVM to consider adoption of audited standalone & consolidated financials for FY2025-26, declaration of dividend, director re-appointment and other routine items.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
207.50 | 2,916 Cr | 19.64 | 1.11 | 0.00 | 5.65 | 8.58 | 2.67 | ||
609.00 | 2,793 Cr | 28.96 | 4.30 | 0.37 | 14.86 | 13.47 | 2.88 | ||
393.00 | 2,675 Cr | 13.18 | 1.18 | 0.25 | 8.92 | 10.93 | 6.83 | ||
135.75 | 2,659 Cr | 17.75 | 1.90 | 0.74 | 10.71 | 14.04 | 6.06 | ||
139.50 | 2,585 Cr | 479.66 | 2.93 | 0.72 | 20.85 | 19.46 | 0.47 | ||
88.50 | 2,277 Cr | 7.17 | 0.93 | 2.71 | 12.98 | 6.12 | 4.86 | ||
97.90 | 1,783 Cr | -2.56 | 0.00 | 0.00 | 77.30 | -64.76 | -4.22 | ||
| Median: 7 Co. | — | 139.50 | 2,659 Cr | 17.75 | 1.18 | 0.37 | 12.98 | 10.93 | 2.88 |
